BioSpace News Archive

Drug Development

Exosome Therapeutics Are Paving a Path to Clinical Readiness

Exosomes show potential to treat myriad conditions, including cancer and inflammation, but experts are divided on whether the therapies are ready for the limelight.

March 4, 2024
·
6 min read
·
Sruthi S. Balakrishnan
Drug Development

ALS Treatment Landscape ‘Primed’ with Over 100 Candidates: GlobalData

Amid the limitations of current therapies for amyotrophic lateral sclerosis, a new GlobalData report points to novel disease-modifying drug approaches that could transform the space.

March 4, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Akero Bounces Back in MASH, Posts Positive Mid-Stage Fibrosis Data

New 96-week data show Akero Therapeutics’ efruxifermin can improve fibrosis by at least one stage without metabolic dysfunction-associated steatohepatitis worsening in more patients versus placebo.

March 4, 2024
·
2 min read
·
Tristan Manalac
FDA

J&J Wins Full FDA Approval for Rybrevant, Chemo Combo in NSCLC

Rybrevant has been approved for use with carboplatin and pemetrexed in the first-line treatment of locally advanced or metastatic non-small cell lung cancer with exon 20 insertion mutations in the EGFR gene.

March 4, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Bayer Pays $310M to BridgeBio for ATTR-CM Treatment in Europe

As BridgeBio’s acoramidis inches closer to an FDA approval decision, Bayer on Monday inked a European licensing agreement for the transthyretin amyloid cardiomyopathy treatment.

March 4, 2024
·
2 min read
·
Tyler Patchen
Policy

IRA Drives Pfizer’s Decision to Focus on Biologics, Not Small Molecules

Pfizer’s oncology strategy to build up its biologics portfolio and dramatically reduce small molecules was influenced by the Inflation Reduction Act’s drug price negotiation provisions.

March 4, 2024
·
4 min read
·
Greg Slabodkin
Biotech Bay

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

AnHeart Therapeutics and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor.

March 4, 2024
·
7 min read
Biotech Bay

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Sofwave Medical Ltd is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

March 4, 2024
·
1 min read
Business

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Sera Prognostics Inc. today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20, after the close of the market.

March 4, 2024
·
4 min read
Drug Development

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy

Valo Health, Inc (Valo), a technology company focused on utilizing large scale data and artificial intelligence (AI) driven computation to discover and develop therapeutics, today announced full enrollment in the company’s Phase 2 Spectra clinical trial.

March 4, 2024
·
4 min read